Figure 1.

THRIVE study flow chart. DHRA, Department of Health Risk Assessment; DOAC, direct-acting oral anticoagulant; DVT, deep vein thrombosis; ICER, incremental cost-effectiveness ratio; LMWH, low-molecular-weight heparin; VTE, venous thromboembolism.